Vasopressors and propofol infusion syndrome in severe head trauma.
BACKGROUND
Propofol infusion syndrome (PRIS) is a rare, but lethal complication of high-dose propofol infusions. We undertook this study to evaluate the incidence of PRIS in a cohort of patients with severe head trauma and its relation to the use of vasopressors.


METHODS
We reviewed all patients with severe head trauma admitted to our Neuro-Intensive Care Unit over a 4-year period for use of propofol and vasopressors. Those patients who developed unexplained acidosis, creatine kinase elevation unrelated to trauma, and electrocardiographic changes were considered having PRIS. We investigated the concomitant use of vasopressors while propofol was used and calculated odds ratios for developing PRIS.


RESULTS
We report three adult patients who developed PRIS out of 50 (6%) admitted patients with severe head trauma on propofol infusions. Two of these patients survived and one expired after withdrawal of life support. Concomitant use of vasopressors was associated with development of PRIS in this cohort (odds ratio 29, 95% CI 1.5-581, P < 0.05).


CONCLUSIONS
Awareness and early recognition of PRIS in critically ill neurosurgical patients on vasopressors and daily screening for creatine kinase elevation, unexplained acidosis, or electrocardiographic changes may reduce the incidence and case-fatality.
Smith
Heidi
H
Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Sinson
Grant
G
Varelas
Panayiotis
P
D000138:Acidosis / Q000139:chemically induced; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D006259:Craniocerebral Trauma / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D003402:Creatine Kinase / Q000097:blood; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects; D017809:Fatal Outcome; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D015742:Propofol / Q000008:administration & dosage / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D012720:Severity of Illness Index; D017180:Tachycardia, Ventricular / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*; D055815:Young Adult
D006993:Hypnotics and Sedatives; D014662:Vasoconstrictor Agents; D003402:Creatine Kinase; D015742:Propofol